Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants

J. W. Eikelboom; S. Kozek-Langenecker; A. Exadaktylos; A. Batorova; Z. Boda; F. Christory; I. Gornik; G. Kėkštas; A. Kher; R. Komadina; O. Koval; G. Mitic; T. Novikova; E. Pazvanska; S. Ratobilska; J. Sütt; A. Winder; D. Zateyshchikov

doi:10.1016/j.bja.2017.11.082

Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants

J. W. Eikelboom^*, S. Kozek-Langenecker, A. Exadaktylos, A. Batorova, Z. Boda, F. Christory, I. Gornik, G. Kėkštas, A. Kher, R. Komadina, O. Koval, G. Mitic, T. Novikova, E. Pazvanska, S. Ratobilska, J. Sütt, A. Winder, D. Zateyshchikov

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

17 Scopus citations

Abstract

Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran) and factor Xa (rivaroxaban, apixaban, edoxaban) have been introduced in several clinical indications. Although NOACs have a favourable benefit-risk profile and can be used without routine laboratory monitoring, they are associated–as any anticoagulant–with a risk of bleeding. In addition, treatment may need to be interrupted in patients who need surgery or other procedures. The objective of this article, developed by a multidisciplinary panel of experts in thrombosis and haemostasis, is to provide an update on the management of NOAC-treated patients who experience a bleeding episode or require an urgent procedure. Recent advances in the development of targeted reversal agents are expected to help streamline the management of NOAC-treated patients in whom rapid reversal of anticoagulation is required.

Original language	English
Pages (from-to)	645-656
Number of pages	12
Journal	British Journal of Anaesthesia
Volume	120
Issue number	4
DOIs	https://doi.org/10.1016/j.bja.2017.11.082
State	Published - Apr 2018
Externally published	Yes

Funding

Funders	Funder number
Boehringer Ingelheim Regional Centre Vienna

Keywords

anticoagulants
coagulation monitoring
emergencies
haemorrhage
reversal

Access to Document

10.1016/j.bja.2017.11.082

Cite this

Eikelboom, J. W., Kozek-Langenecker, S., Exadaktylos, A., Batorova, A., Boda, Z., Christory, F., Gornik, I., Kėkštas, G., Kher, A., Komadina, R., Koval, O., Mitic, G., Novikova, T., Pazvanska, E., Ratobilska, S., Sütt, J., Winder, A., & Zateyshchikov, D. (2018). Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. British Journal of Anaesthesia, 120(4), 645-656. https://doi.org/10.1016/j.bja.2017.11.082

@article{ef16a1adbe024f909adc65b8ff66542c,

title = "Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants",

abstract = "Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran) and factor Xa (rivaroxaban, apixaban, edoxaban) have been introduced in several clinical indications. Although NOACs have a favourable benefit-risk profile and can be used without routine laboratory monitoring, they are associated–as any anticoagulant–with a risk of bleeding. In addition, treatment may need to be interrupted in patients who need surgery or other procedures. The objective of this article, developed by a multidisciplinary panel of experts in thrombosis and haemostasis, is to provide an update on the management of NOAC-treated patients who experience a bleeding episode or require an urgent procedure. Recent advances in the development of targeted reversal agents are expected to help streamline the management of NOAC-treated patients in whom rapid reversal of anticoagulation is required.",

keywords = "anticoagulants, coagulation monitoring, emergencies, haemorrhage, reversal",

author = "Eikelboom, {J. W.} and S. Kozek-Langenecker and A. Exadaktylos and A. Batorova and Z. Boda and F. Christory and I. Gornik and G. Kėk{\v s}tas and A. Kher and R. Komadina and O. Koval and G. Mitic and T. Novikova and E. Pazvanska and S. Ratobilska and J. S{\"u}tt and A. Winder and D. Zateyshchikov",

note = "Publisher Copyright: {\textcopyright} 2017 The Author(s)",

year = "2018",

month = apr,

doi = "10.1016/j.bja.2017.11.082",

language = "אנגלית",

volume = "120",

pages = "645--656",

journal = "British Journal of Anaesthesia",

issn = "0007-0912",

publisher = "Elsevier Ltd.",

number = "4",

}

Eikelboom, JW, Kozek-Langenecker, S, Exadaktylos, A, Batorova, A, Boda, Z, Christory, F, Gornik, I, Kėkštas, G, Kher, A, Komadina, R, Koval, O, Mitic, G, Novikova, T, Pazvanska, E, Ratobilska, S, Sütt, J, Winder, A & Zateyshchikov, D 2018, 'Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants', British Journal of Anaesthesia, vol. 120, no. 4, pp. 645-656. https://doi.org/10.1016/j.bja.2017.11.082

TY - JOUR

T1 - Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants

AU - Eikelboom, J. W.

AU - Kozek-Langenecker, S.

AU - Exadaktylos, A.

AU - Batorova, A.

AU - Boda, Z.

AU - Christory, F.

AU - Gornik, I.

AU - Kėkštas, G.

AU - Kher, A.

AU - Komadina, R.

AU - Koval, O.

AU - Mitic, G.

AU - Novikova, T.

AU - Pazvanska, E.

AU - Ratobilska, S.

AU - Sütt, J.

AU - Winder, A.

AU - Zateyshchikov, D.

PY - 2018/4

Y1 - 2018/4

N2 - Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran) and factor Xa (rivaroxaban, apixaban, edoxaban) have been introduced in several clinical indications. Although NOACs have a favourable benefit-risk profile and can be used without routine laboratory monitoring, they are associated–as any anticoagulant–with a risk of bleeding. In addition, treatment may need to be interrupted in patients who need surgery or other procedures. The objective of this article, developed by a multidisciplinary panel of experts in thrombosis and haemostasis, is to provide an update on the management of NOAC-treated patients who experience a bleeding episode or require an urgent procedure. Recent advances in the development of targeted reversal agents are expected to help streamline the management of NOAC-treated patients in whom rapid reversal of anticoagulation is required.

AB - Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran) and factor Xa (rivaroxaban, apixaban, edoxaban) have been introduced in several clinical indications. Although NOACs have a favourable benefit-risk profile and can be used without routine laboratory monitoring, they are associated–as any anticoagulant–with a risk of bleeding. In addition, treatment may need to be interrupted in patients who need surgery or other procedures. The objective of this article, developed by a multidisciplinary panel of experts in thrombosis and haemostasis, is to provide an update on the management of NOAC-treated patients who experience a bleeding episode or require an urgent procedure. Recent advances in the development of targeted reversal agents are expected to help streamline the management of NOAC-treated patients in whom rapid reversal of anticoagulation is required.

KW - anticoagulants

KW - coagulation monitoring

KW - emergencies

KW - haemorrhage

KW - reversal

UR - http://www.scopus.com/inward/record.url?scp=85045918679&partnerID=8YFLogxK

U2 - 10.1016/j.bja.2017.11.082

DO - 10.1016/j.bja.2017.11.082

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 29576106

AN - SCOPUS:85045918679

SN - 0007-0912

VL - 120

SP - 645

EP - 656

JO - British Journal of Anaesthesia

JF - British Journal of Anaesthesia

IS - 4

ER -

Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants

Abstract

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this